95 results
10-K
2024 FY
IXHL
Incannex Healthcare Limited
30 Sep 24
Annual report
7:30am
and increased risk of death or injury due to traffic accidents resulting from excessive daytime sleepiness. The substantial patient and society costs … liable for injury caused to individuals exposed to or taking our drug candidates; and
our reputation may suffer.
In addition, adverse side effects
8-K
EX-99.1
IXHL
Incannex Healthcare Limited
5 Aug 24
FDA Review of PsiGAD2 IND complete; clinical trial for Psilocybin Assisted Psychotherapy in Patients with Generalised Anxiety Disorder to Proceed
8:15am
apnoea (OSA), traumatic brain injury (TBI) and concussion, lung inflammation (ARDS, COPD, asthma, bronchitis), rheumatoid arthritis, inflammatory bowel
8-K
EX-99.1
IXHL
Incannex Healthcare Limited
30 Jul 24
Dosing completed in 115 participant bioavailability/bioequivalence clinical trial for proprietary sleep apnea drug candidate IHL-42X
9:00am
), traumatic brain injury (TBI) and concussion, lung inflammation (ARDS, COPD, asthma, bronchitis), rheumatoid arthritis, inflammatory bowel disease
S-1/A
IXHL
Incannex Healthcare Limited
17 Jul 24
IPO registration (amended)
8:47am
sleep apnea, traumatic brain injury and concussion, rheumatoid arthritis, inflammatory bowel disease and inflammatory lung conditions. We are also … may result in:
decreased demand for our drug candidates;
injury to our reputation;
withdrawal of clinical trial participants;
costs of related
S-1
IXHL
Incannex Healthcare Limited
3 Jul 24
IPO registration
6:29am
, traumatic brain injury and concussion, rheumatoid arthritis, inflammatory bowel disease and inflammatory lung conditions. We are also developing … or eventual outcome, liability claims may result in:
decreased demand for our drug candidates;
injury to our reputation;
withdrawal of clinical trial
8-K
EX-99.1
8ecqincxck 0nqb
30 May 24
Other Events
8:30am
8-K
EX-99.1
t1so7
7 May 24
Incannex Complete Successful Pre-IND Meeting with the FDA for CannQuit-O for treatment of opioid use disorder
8:30am
8-K
EX-99.1
d5yqxhu59xf7hm7aa12
16 Apr 24
Incannex Healthcare Inc. Quarterly Update, Q1 2024
9:30am
8-K
EX-99.1
f881ybyxqprc f0i
28 Feb 24
Incannex Announces Positive Topline Results from Phase 2 Psi-GAD1 Clinical Trial of Psilocybin in Generalised Anxiety Disorder
7:42am
8-K
EX-99.1
jwcsw 8d756g3
16 Feb 24
Incannex Complete Successful Pre-IND Meeting with the FDA for CannQuit-N; a Novel Solution for Tobacco Smoking Cessation
8:00am
8-K
EX-99.1
x451ygdv
1 Feb 24
Other Events
7:30am
8-K
EX-99.1
ep98ukhfgojgt6kzbmrm
24 Jan 24
Other Events
4:30pm
8-K
EX-99.1
rtepp uej60ux8nha
18 Jan 24
Other Events
9:08am
8-K
EX-99.1
h6c s5apbvvc6ger4
17 Jan 24
Incannex Receives IRB Approval for the RePOSA Phase 2/3 Clinical Trial Protocol to Assess IHL-42X Drug in Patients with Obstructive Sleep Apnea
6:05am
8-K
EX-99.1
gmuu4n2uuygj83j8
22 Dec 23
Clarion Clinics Receives Ethics Board Endorsment for the First Dedicated Psychedelic-assisted Therapy Clinic In Australia
6:07am
8-K
EX-10.2
448 1y96v
29 Nov 23
Entry into a Material Definitive Agreement
4:36pm
8-K
EX-99.2
8bl49hd2w9y6nq1u90i
29 Nov 23
Entry into a Material Definitive Agreement
4:36pm
6-K
EX-99.1
eli zcqpino
24 Nov 23
Report of Foreign Private Issuer
6:02am
6-K
EX-99.1
mxl3re
16 Nov 23
Computershare will be appointed US Transfer Agent and Registrar to facilitate Transfer Capabilities for Nasdaq-listed shares
9:33pm
6-K
EX-99.1
5aexuq 3ybm8j
16 Nov 23
Report of Foreign Private Issuer
9:31pm